It turned out that the activity of pathway proteins, β-catenin and p-GSK3β, was inhibited after treatment with Afatinib, as well as Cyclin D1 expression, which means that Afatinib can affect the proliferation of NSCLC cells through Wnt/β-catenin pathway. The gene discussed is CCND1; the disease is non-small cell lung carcinoma.